Hippocampal sclerosis of aging (HS-Aging) is a neurodegenerative disease that mimics Alzheimer disease (AD) clinically and has a prevalence rivaling AD in advanced age. Whereas clinical biomarkers are not yet optimized, HS-Aging has distinctive pathological features that distinguish it from other diseases with ''hippocampal sclerosis'' pathology, such as epilepsy, cerebrovascular perturbations, and frontotemporal lobar degeneration. By definition, HS-Aging brains show neuronal cell loss and gliosis in the hippocampal formation out of proportion to AD-type pathology; it is strongly associated with aberrant TDP-43 pathology and arteriolosclerosis. Here, we describe 2 cases of ''segmental'' HS-Aging in which ''sclerosis'' in the hippocampus was evident only in a subset of brain sections by hematoxylin and eosin (H&E) stain. In these cases, TDP-43 pathology was more widespread on immunostained sections than the neuronal cell loss and gliosis seen in H&E stains. The 2 patients were cognitively intact at baseline and were tracked longitudinally over a decade using cognitive studies with at least 1 neuroimaging scan. We discuss the relevant HS-Aging literature, which indicates the need for a clearer consensus-based delineation of ''hippocampal sclerosis'' and TDP-43 pathologies in aged subjects.
INTRODUCTION
Hippocampal sclerosis of aging (HS-Aging) is a neurodegenerative disease with high morbidity that usually affects individuals who survive past age 80 years (1Y6). The diagnosis of HS-Aging rests primarily on neuropathological findings in hematoxylin and eosin (H&E) stains using consensusbased criteria (1, 7) ; these include cell loss, gliosis, and atrophy in the hippocampal formation that is out of proportion to Alzheimer disease (AD)Ytype pathology. HS-Aging is a common pathology among older individuals, but its clinical manifestations are often incorrectly attributed to AD (2, 4, 5, 8) . Hence, there is a need for better understanding of the HS-Aging disease spectrum.
Although not part of current consensus-based diagnostic criteria, TAR-DNA binding protein 43 (TDP-43) pathology is strongly linked to HS-Aging (1, 5, 9Y13) . TDP-43 is a nucleotide-binding protein that is normally enriched in the nucleus of neurons (12, 14) . In HS-Aging, affected neurons display loss of nuclear TDP-43, accumulation of cytoplasmic phosphorylated TDP-43 inclusion bodies, and aberrant TDP-43 in neurites (1) . This aberrant TDP-43 immunostaining is often seen in hippocampal dentate granule cells, CA1 hippocampal sector, subiculum, and amygdala (1, 10) . TDP-43 pathology is a key difference between HS-Aging and other diseases with hippocampal sclerosis (HS) pathology, such as epilepsy and vascular insufficiency, which lack aberrant TDP-43 staining (1, 15) . We have found that if bilateral entorhinal cortex sections are assessed, approximately 90% of HS-Aging cases show aberrant TDP-43 pathology, whereas only 10% of non-HS-Aging cases show TDP-43 pathology (1) . We have also shown that individuals with ''unilateral'' HS-Aging (by H&E stain) show aberrant TDP-43 inclusions in both the affected and contralateral side (1) . This asymmetric HS (i.e., one-sided neuronal loss) observed in H&E-stained sections with bilateral TDP-43 immunopositivity provides insight into potentially early stages of HS-Aging pathology: hippocampal TDP-43 pathology without widespread ''sclerosis'' (5) .
To raise awareness of the clinical-pathological features of TDP-43 immunoreactivity with only segmental ''sclerotic'' changes, we describe the findings from 2 research volunteer subjects from the University of Kentucky Alzheimer's Disease Center (UK-ADC) longitudinal cohort. We define segmental HS-Aging as focal cell loss in the CA1 and/or subicular region(s), with astrocytosis seen on some but not all hippocampal sections on H&E and with aberrant TDP-43 immunostaining in the hippocampal formation. Both segmental HS-Aging cases were followed from initial cognitively intact status to death. Clinical, cognitive, imaging, and neuropathological findings are presented. We also review the relevant literature and emphasize that these cases are not unusual.
CLINICAL AND NEUROPATHOLOGICAL ASSESSMENTS
Details of UK-ADC recruitment, inclusion/exclusion criteria, clinical assessments, cognitive testing, and neuropathological protocols have been described (16, 17) . Briefly, as part of a longitudinal study, the 2 individuals in this study FIGURE 1 . Mini-Mental State (MMSE) and T-scores from longitudinal neurocognitive assessments in animal fluency, immediate, and delayed memory tasks. For the T-scores, mean = 50, SD = 10. Standardization of t-scores is based on results from age-matched nondemented individuals. The age at which mild cognitive impairment (MCI) diagnosis, neuroimaging scans, and probable Alzheimer disease diagnosis were made are indicated by red, blue, and green asterisks, respectively. Note that memory scores declined more than verbal fluency.
consented to annual mental status testing, physical examinations, and postmortem brain donation (18) . All protocols were performed with UK institutional review board approval. Clinical data from annual cognitive assessments were examined using normative values from baseline assessments of 648 healthy aging volunteers. Cognitive assessments reported here included measures of category verbal fluency, immediate memory and learning, and delayed recall scores incorporated from word list learning and paragraph tests (17, 19) . Raw scores from each measure were transformed to T-scores based on the average baseline performance of the larger sample (19Y21). The derived T-scores (mean = 50, SD = 10) incorporated adjustments for age, sex, and education. This method allowed for direct comparisons between each case. MiniMental State Exam (MMSE) scores (22) are presented as raw scores for comparative purposes. Neuroimaging studies were obtained at the request of the neurologist. Imaging modalities included magnetic resonance imaging (MRI)-T1 weighted imaging with or without contrast, MRI-T2-weighted imaging, and CT imaging without contrast.
Neuropathological assessments were performed at UK-ADC using previously described methodology (1, 18, 23) . At least 28 sections were taken from various brain areas. At least 4 areas from the medial temporal lobes were sectioned: the amygdala, entorhinal cortex, and rostral and caudal hippocampi including the level of the lateral geniculate nucleus from both left and right sides. After formalin fixation and paraffin embedding, 8-Km-thick sections were stained with H&E. Immunostains for PHF-1 (gift from Dr. Peter Davies, Feinstein Institute for Medical Research, Manhasset, NY; 1:500 dilution) and amyloid-A (Vector Laboratories, Burlingame, CA; 1:100 dilution) were performed and used to assess neuritic plaques, amyloid A (AA), and neurofibrillary tangles following the National Institute on Aging-Alzheimer's Association (NIA-AA) consensus recommendations (7). Anti->-synuclein (Vector Laboratories; 1:40 dilution) immunohistochemistry was used for assessing Lewy body pathology. Anti-glial fibrillary acidic protein (Novocastra, Buffalo Grove, IL) immunostaining was performed to demonstrate reactive astrocytes. The anti-phospho TDP-43 antibody used was a gift from Dr. Manuela Neumann (University of Tubingen, Tubingen, Germany; 1:500 dilution).
RESEARCH SUBJECTS Case ''F''
An 82-year-old woman was initially recruited as a cognitively intact research volunteer. Her father had been clinically diagnosed with AD and died at age 73 years. Her medical history included hypertension, coronary artery disease, hyperlipidemia, and hypothyroidism, all of which were treated medically. She had smoked (25 pack/year history) and denied excessive alcohol drinking.
At the age of 88, she received a clinical consensus diagnosis of amnestic mild cognitive impairment (Fig. 1) . Because of her cognitive decline, MRI T1-and T2-weighted images with and without contrast were obtained at age 88 (Fig. 2) . Radiological impressions from images included moderate generalized cerebral atrophy with cerebellar atrophy, mild ex vacuo ventricular dilatation, and multiple confluent areas of supratentorial white matter hyperintensities. The latter finding was considered consistent with chronic microvascular infarcts.
Near her 90th birthday, she was having difficulties with finances and became paranoid, stating that people were stealing from her. Donepezil was initiated at that time. By age 91, she was no longer driving, although she was still performing simple chores in the home. Her cognition continued to decline, and she began to struggle increasingly with higher-order executive tasks. Her cognitive test results show a steady decline in delayed memory (1 SD below the mean), with preserved immediate memory and animal fluency tasks ( Fig. 1) . At age 94, she was diagnosed with probable AD and was wheelchair dependent. By this time, she required assistance with all activities of daily living including bathing. She died at age 95.
Neuropathological findings are shown in Figures 3 and 4. For comparison, the hippocampus of a nondemented individual is shown in Figure 3A . An unrelated HS-Aging case is shown in Figure 3D demonstrating diffuse neuronal loss, neuropil rarefaction (Fig. 3E ), and astrocytosis (Fig. 3F ). In contrast, Case F showed less generalized hippocampal shrinkage (Fig. 3G) , with segmental neuronal cell loss in the CA1 region (Fig. 3H ) and reactive astrocytosis (Fig. 3I) . In Case F, HS-Aging pathology was predominantly localized in the CA1 region, whereas the comparison case in Figure 3D shows more widespread pathology extending into the subiculum. Case F showed abundant TDP-43-immunoreactive intracellular inclusions and neurites throughout the amygdala, entorhinal cortex, and hippocampus with bilateral TDP-43 immunoreactivity (Fig. 4D ). TDP-43 inclusions were more widespread than neurites (blue outlined areas) in the brain sections (Fig. 4D) .
Assessments using the NIA-AA consensus protocol for AD workup (7) 
Case ''M''
A 74-year-old man was initially recruited as a cognitively intact research volunteer. He had reported that his mother had dementia with an unknown age of diagnosis. His medical history was significant for hypertension and benign prostatic hypertrophy. He smoked (50 pack/years) and drank alcohol (3Y4 drinks/day). His cognitive performance was relatively unremarkable until age 82, when he was diagnosed with mild cognitive impairment based on a consensus review of his symptoms (Fig. 1) .
A workup at age 83 led to a diagnosis of mixed probable AD and vascular disease. He began treatment with donepezil at this time. At age 86, he began to struggle with higher order activities including driving. By age 87, he was no longer driving, but he was still intact with respect to most other activities of daily living; memantine was added to his medications at that time. By age 88, he needed help with most activities of daily living including bathing.
At his last UK-ADC clinic visit, his MMSE score was 19 with mild behavioral issues of impulsivity. Longitudinal cognitive test results showed a steady decline in immediate and delayed memory tasks (3 standard deviations below the mean by age 86) with preserved animal fluency performance (Fig. 1) . After a fall at age 89, CT imaging without contrast was obtained. This image revealed a chronic left subdural hematoma, periventricular white matter hypodensity, and generalized brain volume loss (Fig. 2) . The patient passed away later that year at age 89.
Neuropathological hippocampal autopsy findings are shown in Figures 3 and 4 . There was focal hippocampal shrinkage (Fig. 3J) , with segmental neuronal cell loss in the CA1 region (Fig. 3K ) and astrocytic gliosis (Fig. 3L) . Aberrant TDP-43 immunoreactivity was seen within the amygdala bilaterally and the left rostral and caudal entorhinal cortices (Fig. 4E ). In addition, there were intracellular TDP-43-positive cytoplasmic ''preinclusions'' (green triangles) in the hippocampus bilaterally and in the right entorhinal cortex (Fig. 4E) . TDP-43 intracellular inclusion bodies were more widespread than neurites (blue outlined areas) in the brain sections (Fig. 4E) .
DISCUSSION AND REVIEW OF THE LITERATURE
There is an evolving appreciation of the large impact of HS-Aging on public health, particularly among the oldest-old: approximately 10% to 25% of persons older than 85 demonstrate this pathology at autopsy (1Y5, 8, 11, 24Y29 ). Here, we describe the detailed findings in 2 subjects with segmental HS-Aging that may represent either early HS-Aging pathology or be those of a subset of cases that develop TDP-43 pathology without widespread hippocampal changes, thereby meeting current criteria for HS. These segmental HS-Aging patterns are frequently seen in our autopsy seriesVunderscored by the observation that approximately one half of our HS-Aging cases are unilateral on H&E stains (1)Valthough pathogenesis of these patterns is not well understood.
There are inherent limitations of this study. The diagnosis of segmental HS-Aging was made primarily using H&E stain, but the ''sclerotic'' changes are difficult to discriminate with precision. Zinc transporter 3 immunostaining, choline acetyltransferase immunostaining, and Hirano silver staining have been used to delineate between CA3YCA2, CA2YCA1, and CA1Ysubiculum respectively, in HS cases (30) . These stains can be used in future segmental HS-Aging studies to help determine which hippocampal regions are initially and/or most affected. The segmental HS-Aging pathology in these cases may not fully explain the cognitive declines seen years before death. Case F showed evidence of multifocal cerebrovascular disease, and Case M showed intermediate AD pathology with severe multifocal cerebrovascular disease, which may help explain the dementia. These cases indicate how frequent comorbidities, especially AD and cerebrovascular neuropathologic changes, could strongly alter the pattern of tested cognitive domains. Both cases in the present study showed TDP-43 pathology in the amygdala, entorhinal cortex, and hippocampus. According to reports from different research centers, hippocampal TDP-43 pathology with or without reported HS contributes to an additive component of cognitive impairment (14, 31Y35) . Therefore, it is reasonable to infer that the TDP-43 pathology seen in these individuals may partly explain their cognitive deterioration. Because of the lack of a clear consensus in the field on HS-Aging categorization and ''boundary zones'' between other neurodegenerative diseases, we highlight HS-Aging in relationship to prehippocampal sclerosis (pre-HpScl, a term that has been used to describe early HS-Aging pathology [36] ), frontotemporal lobar degeneration (FTLD) with TDP-43 pathology (FTLD-TDP), AD and cerebrovascular pathologies.
Early HS-Aging or ''Pre-HpScl''
Although information on HS-Aging is rapidly accumulating, nomenclature for this disease is not universal. One group refers to a disease category very similar to HS-Aging as ''HpScl,'' (2, 37, 38) and some may refer to this condition as ''hippocampal sclerosis dementia'' (39) . In a very recent paper, a panel of experts discussed HS-Aging pathologic classification terminology (40); however, the average age of persons used in this consensus recommendation paper were younger (most less than 80 years old) than when HS-Aging prevalence is highest (1). Unfortunately, the term hippocampal sclerosis is itself potentially misleading. The pathologic features are not fully conveyed by the term sclerosis, which signifies ''hardening.'' Furthermore, the pathologic changes of HS-Aging generally extend beyond the hippocampus proper. We reiterate the important point that the term hippocampal sclerosis is widely used to describe multiple distinct diseases, including hippocampal pathology associated with epilepsy, hypoxia, hypoglycemia, FTLD, and others. Well more than 95% of PubMed citations linked to ''hippocampal sclerosis'' are unrelated to HS-Aging, HpScl, or HS dementia. Thus, to prevent confusion (whatever the eventual terminology ends up being), we recommend that it should include a component different from simply ''hippocampal sclerosis.'' Recently, the term pre-HpScl was used to describe hippocampal pathology characterized by none to minimal neuronal loss or extracellular neurofibrillary tangles with abundant TDP-43 pathology (36) . This condition may partially overlap with the ''segmental'' HS-Aging pathology seen in the 2 cases described here. Both articles present cases that show focal neuronal loss and gliosis in CA1 with more widespread TDP-43 pathology in the limbic system. These findings suggest that HS-Aging could be a progressive disease where the initial stages are characterized by the presence of TDP-43 pathology with or without some focal areas of cell loss (Fig. 5) . More broadly, these findings may also be evidence for a presently unnamed ''brain-wide'' disease that is characterized by a spectrum of hippocampal TDP-43 pathologies ( Fig. 5) : TDP-43 pathology, TDP-43 pathology with segmental/focal sclerotic-type changes, and TDP-43 pathology with diffuse HS.
Frontotemporal lobar degenerationYTDP
Aberrant TDP-43 is seen in 65% to 90% of HS-Aging cases (1, 10) . Because of the high prevalence of TDP-43 pathology in HS-Aging cases there is some support for the hypothesis that HS-Aging is closely related to FTLD-TDP (41) . In one study, the prevalence of hippocampal sclerosis in FTLD-TDP was 42% (42) . Moreover, the slender nontapering TDP-43 neurites observed in FTLD-TDP hippocampi (''type A'' pattern) resemble those seen in HS-Aging (42) . In a different study, more than 70% of hippocampal sclerosis cases with TDP-43 pathology had neurites and inclusion bodies the morphology of which resembled that found in FTLD-TDP (10) . Similarly, in Lewy body dementia (LBD) cases with HSAging, the TDP-43 immunohistochemistry pattern was similar to the FTLD-TDP type A pattern (36) . We also note that some human genetic polymorphisms (in GRN and TMEM106B) are risk factors for both FTLD-TDP and HS-Aging pathologies (33, 37, 43Y45) . The TMEM106B polymorphism (rs1990622) was also recently shown to be a risk factor for non-HS TDP-43 pathology (46) . These findings could be argued to support the possibility that HS-Aging and TDP-43 pathology in older people are either pathogenetically linked or represent a frank variant of FTLD.
Although there are areas of overlap, FTLD and HSAging also differ in clinical symptoms, genetic risk factors (discussed in greater detail below), and pathological characteristics. For example, patients with FTLD pathology show clinical manifestations and die at much younger ages than those with HS-Aging pathology (8, 11) . HS-Aging cases tend to lack either the behavioral variant FTD or aphasia symptoms (1, 8) , although late in their disease courses, both of the current 2 cases had features previously linked to frontal cortical dysfunction (i.e., delusions in Case F and impulsivity in Case M) (47Y49). HS-Aging patients were previously shown to demonstrate a group-level neurocognitive profile characterized by higher verbal fluency scores 2 to 5 years before death, as seen in Case F and Case M, dissimilar to nontauopathic FTLD cases (8) .
Pathologically, TDP-43 proteinopathy is specific neither to FTLD-TDP nor HS-Aging because TDP-43 pathology can be seen in Alexander disease, low-grade glial neoplasms, AD/Down syndrome, and brain trauma (15, 50Y54). Thus (perhaps analogous to tau protein and neurofibrillary tangles), there appears to be a ''reactive'' aspect to TDP-43 pathology, although the pathology also seems deleterious when present. Frontotemporal lobar degenerationYTDP cases with HS showed more severe cortical and brainstem atrophy than HSAging cases, which localized to the hippocampus (11). HSAging cases had lower synaptophysin immunoreactivity, greater astrocytic reactivity and microglial reactivity compared with FTLD-TDP with HS cases (11) . It has been suggested that HS-Aging in aged individuals may be a variant of FTLD-TDP (55); however, this does not seem to make sense because if this were true, there should be a very large cohort of individuals who ultimately express the full-fledged FTLD-TDP clinical picture among the aged, and this is not the case. Frontotemporal lobar degeneration is quite rare: there are only approximately 20,000Y30,000 cases in America (75) , around half with FTLD-TDP. This contrasts with HS-Aging, which is extremely prevalent, perhaps affecting more than a million Americans (5, 6, 29, 76) . Furthermore, there is not evidence that the hippocampal pathology shows early clinicaltemporal pattern in FTLD-TDP cases. These findings support the notion that HS-Aging is a distinct pathology from FTLD-TDP, although both diseases show TDP-43 immunoreactivity and HS (Fig. 5) .
Alzheimer Disease
Because TDP-43 pathology is seen in many cases that also have abundant AD pathology, there may be a subset of HS-Aging cases that are best categorized as a variant of AD. TDP-43 positivity can be seen in 14% to 57% of AD cases (14, 34, 53, 54) . More specifically in one study, TDP-43 pathology was seen 9% of familial AD cases, 10% in early onset AD cases, and 29% in late-onset AD cases (53) . Another study showed that increasing TDP-43-immunoreactive pathology correlates with increasing Braak neurofibrillary tangle stages (10) . It has also been shown that some TDP-43 inclusions seen in AD brains colocalize with phospho-tau in the entorhinal cortex and dentate fascia (10) . Because in vivo and in vitro studies have shown that AA and/or tau can promote the misfolding/polymerization of polypeptides (e.g., >-synuclein) (59Y61), it can be speculated that this could occur in late-stages of AD brain pathology (10) . It remains to be seen whether the ''TAD'' staging system of TDP-43 pathology in AD brains or in brains with dementia with Lewy bodies (DLB) pathology (36) is directly relevant to the staging of TDP-43 pathology in HS-Aging. Because all of these pathologic changes (i.e., HS-Aging/TDP-43 pathology, AD, and DLB) are relatively prevalent in community-based samples evaluated to date (in strong contrast to FTLD), they could be coexistent rather than directly linked pathologies (39, 62Y65) .
A counterargument against a specific link between HSAging and AD pathologies is that HS-Aging has no association with APOE or with any other AD-related risk allele (2, 6, 23, 66) . Thus far, there also does not seem to be a genderbased predisposition for HS-Aging (8) . It would be expected that many individuals would manifest both AD and HS-Aging pathologies at autopsy because both pathologies are prevalent in older populations.
Cerebrovascular Disease
Another brain process that has been associated with HSAging pathology is cerebrovascular disease. Dickson and colleagues described cerebrovascular disease pathology in a cohort of 13 individuals with HS-Aging (67). Arteriosclerosis, atherosclerosis, subcortical arteriosclerotic leukoencephalopathy, and cerebral amyloid angiopathy were observed in these cases (3) . We recently showed that arteriolosclerosis, characterized by thickened and/or dysmorphic arterioles in the brain, is associated with HS-Aging pathology; in the gray matter, the mean vessel wall thickness was significantly larger in HS-Aging cases compared with that of nonYHS-Aging cases (68) .
There is circumstantial support from genetic studies for a mechanism linking cerebrovascular pathology with HSAging. The only 2 genomics studies that used HS in aged persons as a genome-wide association analysis endophenotype reported risk alleles at genomic loci in potassium channel regulating genes ABCC9 and KCNMB2, previously unrelated to FTLD (43, 69) . We recently replicated the observation that ABCC9 polymorphism is associated with HS-Aging pathology (44) . The ABCC9 polypeptide is physiologically active in arteriolar smooth muscle (70, 71) . Therefore, it is possible that ABCC9 dysregulation leads to arteriolosclerosis, which then may contribute to the pathogenesis of HS-Aging. ABCC9/SUR2 is an attractive candidate for therapeutic strategies because it is a well-established ''druggable target.'' Both agonists (nicorandil, diazoxide, and iptakalim) and antagonists (sulfonylurea drugs) have been applied in clinical trials (72, 73) . Their potential for repurposing for HS-Aging is an active research area in our laboratory.
Coincidentally, both cases in the present study showed cerebrovascular disease including arteriolosclerosis, which may have partially accounted for their progressive cognitive decline. In sum, we infer that the association between arteriolosclerosis and HS-Aging provides added support for a ''brain-wide'' disease that affects both small blood vessels and hippocampal structures and leads to TDP-43 pathology in the aged brain (Fig. 5) .
CONCLUSIONS
We present 2 cases that show what we consider to be either early stages of HS-Aging pathology or possibly a variant of a brain-wide disease characterized by arteriolosclerosis and TDP-43 pathology affecting the limbic system (Fig. 5) . These 2 cases taken together with other articles describing hippocampal TDP-43 pathology in LBD and AD brains (36, 74) suggest the need for a consensus definition regarding the spectrum of pathologies with TDP-43 and HS seen in the aged human brain. HS-Aging is a prevalent neurodegenerative disease, the specific genetic, neuroimaging, symptomatology and pathologic characteristics of which are only beginning to be understood. We conclude that careful clinical-neuropathological correlations may assist in the overall goal of developing strategies to diagnose and treat individuals who have this debilitating illness.
